← Eichor
Condition: B Cell Lymphoblastic Leukemia Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: B Cell Lymphoblastic Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06754267Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Phase 2 · 4 location(s) · Dana-Farber Cancer Institute · NCT05168930AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · 50 location(s) · Eli Lilly and Company · NCT07218341Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod
Phase N/A · 8 location(s) · Bristol-Myers Squibb · NCT06357754Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Le
Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07061951Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu
Phase 3 · 460 location(s) · Alliance for Clinical Trials in Oncology · NCT03150693A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Phase N/A · 24 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04867915Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Phase 2 · 1 location(s) · Zulfa Omer · NCT07014917A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 187 location(s) · BeOne Medicines · NCT06943872Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06554626A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.